In another recent combined cohort of 536 patients with KRAS-mutant lung adenocarcinoma, both STK11 and KEAP1 mutations in the presence of a KRAS mutation were associated with poor response rates to anti-PD(L)1 inhibitors [74]. This evidence concerns the gene KRAS and lung adenocarcinoma.